Welcome to Phoenix Rising!
Created in 2008, Phoenix Rising is the largest and oldest forum dedicated to furthering the understanding of, and finding treatments for, complex chronic illnesses such as chronic fatigue syndrome (ME/CFS), fibromyalgia, long COVID, postural orthostatic tachycardia syndrome (POTS), mast cell activation syndrome (MCAS), and allied diseases.
To become a member, simply click the Register button at the top right.
Tauroursodeoxycholic acid inhibits experimental colitis by preventing early intestinal epithelial cell death.
Abstract
Ulcerative colitis (UC) is characterized by increased epithelial cell death and subsequent breakdown of the intestinal epithelial barrier, which perpetuates chronic intestinal inflammation. Since fecal bile acid dysmetabolism is associated with UC and tauroursodeoxycholic acid (TUDCA) has been shown to improve murine colitis, we evaluated the effect of TUDCA on intestinal epithelial cell death in a mouse model of UC-like barrier dysfunction elicited by dextran sulfate sodium (DSS). We identified the prevention of colonic caspase-3 induction, a key proapoptotic marker which was also over-activated in UC, as the earliest event resulting in a clear clinical benefit. Whereas vehicle-treated mice showed a cumulative mortality of 40%, all TUDCA-treated mice survived the DSS experiment during a 14-day follow-up period. In line with a barrier protective effect, TUDCA decreased bacterial translocation to the spleen and stimulated mucin production. Similarly, TUDCA inhibited lipopolysaccharide-induced intestinal permeability and associated enterocyte apoptosis. The anti-apoptotic effect was confirmed in vitro by a dose-dependent inhibition of both receptor-dependent (using tumor necrosis factor and Fas ligand) and receptor-independent (staurosporine) caspase-3 induction in HT29 colonic epithelial cells. These data imply that caspase-3 activation is an early marker of colitis that is prevented by TUDCA treatment. These data, together with the previously reported beneficial effect in colitis, suggest that TUDCA could be an add-on strategy to current immunosuppressive treatment of UC patients.
I realize that it's ultimately all just hit and miss but I still feel compelled to keep searching for anything that may help provide relief. I've had this condition for over 20 years and, for some reason, I'm actually more hopeful now than ever before.
Well, I'm not surprised that most diseases associated with microbiome research are bowel related. But if you run the search again in a few years, I think you will find quite a few more neurological or immunological diseases there.
I found this information but I have no idea how to translate the math...AOR contains "500,000 organisms" of clostridium butyricum; Miyarisan contains 180mg, per dose. Does anybody know how to compare these numbers?
Minimum CBM 588 content per tablet
Standard Miya-Pro Tablets = Miyarisan Tablets - ≥3x105
Strong Miya-Pro Tablets = Strong Miyarisan Tablets - ≥4.5x105
180mg per daily dose (18 tabs), so 10mg a pop. Don't know what that translates to in organisms.AOR contains "500,000 organisms" of clostridium butyricum; Miyarisan contains 180mg, per dose. Does anybody know how to compare these numbers?
I found this information but I have no idea how to translate the math...
Question for all the microbiome gurus: right now am having severe MCAS reactions to the point of almost not being able to tolerate any foods. I asked part of this question in the RS thread but now have a slightly different question.
If I was going to try a probiotic (right now not taking any and have tried many kinds in the last two years) would it be better for me to try Bifido Infantis (Align) which is supposed to help MCAS reactions or to try Clostridium Butyricum which is sounding like a miracle drug from this thread. I briefly tried Prescript Assist and had no problems with it but when my MCAS stuff got out of control, I stopped about 11 supplements including PA just to be safe.
Would love to hear any thoughts on this. Thank you in advance.